Novel method for preparing S-pantoprazole and salt

Abstract

The invention discloses a novel method for preparing S-pantoprazole and salt, comprising the following steps: chiral separation reagents S-1,1,2-triphenyl-1,2-glycol and racemic pantoprazole react in an appropriate solvent, and the S-pantoprazole.S-1,1,2-triphenyl-1,2-glycol compound deposition is produced by filtering; the compound is dissociated by using alkali to remove S-1,1,2- triphenyl-1,2- glycol, then is neutralized by using acid, and neutral S-pantoprazole is obtained by filtering; and if S-pantoprazole salt is further required to be prepared, the S-pantoprazole prepared in the step (3) reacts with corresponding alkali in an appropriate solvent to obtain the S-pantoprazole salt. The method has high yield, high proportion of single isomer, simple technology, and convenient industrial production.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a new preparation method of S-pantoprazole and its salt. Background technique [0002] Pantoprazole (pantoprazole), the proton pump inhibitor approved by FDA on February 2, 2000, is used for the treatment of esophageal reflux. Its chemical name is: 5-(difluoromethoxy)-2-{[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl}benzimidazole. The sulfur atom of the sulfone group is a chiral center, so there is a pair of optical enantiomers. Proton pump inhibitors with similar structures include omeprazole, lansoprazole, rabeprazole, etc. [0003] The above-mentioned sulfoxide compounds are usually prepared by oxidizing the corresponding thioether compounds to obtain a racemic mixture. Existing studies have shown that the curative effect is better than that of the racemate when administered with a single optical isomer of S-(-). Form of administration, and can reduce the dosage an...

AI Technical Summary

Problems solved by technology

[0022] In the prior art, the chiral oxidation method has become the main research direction in recent years, but the preparation process of the chiral reagent used is complicated and expensive, and the enantiomeric selectivity of the product after oxidation is generally only 92-99% ee, It still contains some R isomers, and it is difficult to meet the requirements of the pharmaceutical industry for a single enantiomer greater than 99%, and often requires further separation and purification before it can be used medicinally

Images